Jubilant Biosys Limited
Giuliano Perfetti has held various senior executive positions throughout their career. Giuliano is currently serving as the Chief Executive Officer at Jubilant Biosys Limited since September 2021. Prior to that, they worked as the Chief Commercial Officer at Holding FIS - Chemical BU and Senior Director Sales, Marketing & BD at FIS at F.I.S. - Fabbrica Italiana Sintetici S.p.A. from March 2014 to September 2021. Giuliano also served as the Sales & Marketing Director at Euticals Group from February 2012 to February 2014. Earlier in their career, they worked at AstraZeneca as a Marketing Director, Marketing Manager for Gastrointestinal & Respiratory, and Strategic Planning Manager. Giuliano began their career at Accenture, where they worked as a Manager, Consultant, and Senior Business Analyst in Strategic Consulting. Prior to that, they worked as a Process & Organization Consultant at Gruppo Formula.
Giuliano Perfetti completed their education at several prestigious institutions. Giuliano pursued Scenario Planning at SDA Bocconi until 2002, and From Strategy to Value at Cranfield School of Management until 2001. Giuliano obtained a degree in Economics from the University of Rome Tor Vergata, graduating with honors in 1999. It is unclear if they pursued any further education at Cranfield School of Management.
This person is not in any offices
Jubilant Biosys Limited
1 followers
Jubilant Biosys Ltd (JBL) offers end-to-end CRDMO solutions in Structural Biology, Computational Chemistry, Medicinal & Synthetic Chemistry, in-vitro and in-vivo Biology, DMPK, Toxicology, Process R&D & Manufacturing to various Biotech & Pharma companies pursuing drug discovery, development and manufacturing. Jubilant Biosys Limited (JBL) is a subsidiary of Jubilant Pharmova, serving the global life sciences, agrochemicals and specialty chemicals industry through its research centers & manufacturing facilities in India. Jubilant’s services in discovery research include; Jubilant’s services in discovery research includes; • Target Identification/Target Validation to Lead Optimization/ Preclinical candidate, for multiple therapeutic areas viz; Oncology, Metabolic Disorders, CNS, Pain and Inflammation. • Functional services comprising of computational chemistry/ molecular modeling, medicinal chemistry, synthetic chemistry, scale-up (Non-GMP & GMP), structural biology, ADME-PK,in-vitro and in-vivo biology and IND enabling GLP toxicology.